Anadrol,Buy Anadrol,Buy Steroids,Effects of Steroids
headerimage2
Home      |          Services      |     Resources      |     Site Map      |     Contact US
                  MENU
icon

Anadrol 50

icon Anadrol side effects
icon Buy anadrol
icon Anadrol for in
icon Anadrol cycle
icon Anadrol 50 oxymetholone
icon Anadrol 50 steroid
icon

Anadrol bold

icon Anadrol 75
icon Anadrol scion
icon Anadrol pill
icon Anadrol 50 side effects
   
  Featured Links
 
Anabolic Steroids
Buy Steroids
Buy Steroids
Steroid Abuse
   
Anadrol 50:

Anadrol 50 is the very strongest and at the same time, also the most effective oral steroid. The Anadrol 50 compound has an extremely high androgenic effect, which goes hand in hand with an extremely intense anabolic component. For this reason, dramatic gains in strength and muscle mass can be achieved in a very short time. An increase in body weight of 10 - 15 pounds or more in only 14 days is not un-usual.  

By the use of Anadrol 50, water retention is considerable, so that the muscle diameter quickly increases and the user gets a massive appearance within record time. Since the muscle cell draws a lot of water, the entire muscle system of most athletes looks smooth, in part even puffy. Anadrol does not cause a qualitative muscle gain but rather a quantitative one, which in the off-season is quite welcome. 

Anadrol "lubricates" the joints since water is stored there as well. On the one hand this is a factor in the enormous increase of strength and, on the other hand, it allows athletes with joint problems a painless workout. Power lifters in the higher weight classes are sold on Anadrol. A strict diet, together with the simultaneous intake of Nolvadex and Proviron, can significantly reduce water retention so that a distinct increase in the solid muscles is possible.  

By taking Anadrol the athlete experiences an enormous "pump effect" during the workout in the exercised muscles. The blood volume in the body is significantly elevated causing a higher blood supply to the muscles during workout. Anadrol increases the number of red blood cells, allowing the muscle to absorb more oxygen. The muscle thus has a higher endurance and performance level. 

The highly androgenic effect of Anadrol stimulates the regeneration of the body so that the often-feared "over-training" is unlikely. Anadrol helps more than any other steroid during dieting to maintain the muscle mass and to allow an intense workout. Many bodybuilders therefore use it up to about one week before a competition, solving the problem of water retention by taking anti-estrogens and diuretics so that they will appear bulky and hard when in the limelight.       

Like methandrostenolone (Dianabol), oxymetholone ( anadrol ) does not bind well to the androgen receptor (AR), and most of the anabolism it provides is via non-AR-mediated effects. It is therefore a Class II steroid and is best stacked with a Class I steroid. The drug appears to give the same benefits as Dianabol. Unlike Dianabol, however, it seems that anadrol is progestagenic. It has been observed to cause nipple soreness or to aggravate gynecomastia even in the presence of high dose antiestrogens, strongly suggesting that the effect is not estrogenic. That effect can be reduced by concurrent use of stanozolol (Winstrol), which is anti-progestagenic. This progestagenic effect of oxymetholone is only a concern when using aromatizing steroids. With androgens such as Primobolan, anadrol stacks very nicely and is a surprisingly friendly drug. In contrast, with testosterone it is a very harsh drug.
Oxymetholone does not convert to estrogen, and thus antiestrogens are not required if no aromatizable AAS are being used. However, in concert with aromatizing drugs, oxymetholone is notorious for worsening "estrogenic" symptoms, possibly by producing progestagenic symptoms which the bodybuilder confuses as estrogenic, or by altering estrogen metabolism, or by upregulating aromatase.
Compared to what bodybuilders expect of it, the drug is reasonably mild when no aromatizing steroids are present. I consider its potency approximately comparable to Dianabol. It is not unusual for a first time user to do quite well on an oxymetholone-only cycle, but more advanced users will want to stack with another steroid. Typical use is 50-150 mg/day, which should be divided into several doses per day.
Because oxymetholone is 17-alkylated, it is stressful to the liver. It is better to limit use to no more than 6 weeks or preferably four weeks before taking a break of at least equal length. Many users feel that it is more effectively used in the beginning parts of the cycle, rather than in the last few weeks.


Trivial name
Oxymetholone ( Anadrol )
Systematic name
5-alpha,17-beta-Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-
CAS number
434-07-1
ATC code
A14AA05
Merck Index Number
7036
Chemical formula
C21H32O3
Molecular weight
332.477 g/mol
Bioavailability
95%
Metabolism
Hepatic
Elimination half-life
9 hours
Excretion
Urinary: 95%
Pregnancy category
X
Legal status
Prescription only (US)
Controlled substance
Yes, DEA Schedule III (US)
Routes of administration
Oral

 
Lilly Announces Completion of SGX Acquisition
INDIANAPOLIS, Ind., August 20, 2008 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it has completed the acquisition of SGX Pharmaceuticals, Inc. , a San Diego-based biotechnology company focused on drug discovery and...


Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
SAN DIEGO--(BUSINESS WIRE)--Aug 20, 2008 - A Virginia man yesterday filed what is believed to be the first personal injury lawsuit stemming from injuries associated with the use of Byetta(R), an injectable medication for diabetes. Victor Deleon...


Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma
Elotuzumab Antibody Designed to Target Highly Expressed Cell Surface Protein and Selectively Kill Multiple Myeloma Cells // PRINCETON, N.J. & REDWOOD CITY, Calif., August 19, 2008 - Bristol-Myers Squibb Company (NYSE: BMY) and PDL...


Tadalafil Shows Promise for Relief of Lower Urinary Tract Symptoms Associated With BPH
NEW YORK, August 19, 2008 - Men with signs of benign prostatic hyperplasia (BPH) can be helped with a daily dose of erectile dysfunction drug tadalafil (Cialis) to relieve associated lower urinary tract symptoms (LUTS), according to a new...


Video: Asmanex Twisthaler 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
ASMANEX is the first and only once-daily inhaled corticosteroid inhaler approved for children as young as age 4 KENILWORTH, N.J., August 19, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that ASMANEX(R) TWISTHALER(R) 110...


FDA Updates the Information for Healthcare Professionals Sheet for Byetta (exenatide)
Information for Healthcare Professionals Exenatide (marketed as Byetta) Update 8/18/2008: Since issuing Information for Healthcare Professionals in October 2007, FDA has received reports of 6 cases of hemorrhagic or necrotizing...


Forbes Medi-Tech Announces Sale of Pharmaceutical Assets
Company Focuses on Building Its Revenue-Generating Nutraceutical Business VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 18, 2008) - Forbes Medi-Tech Inc. (TSX:FMI)(NASDAQ:FMTI) ("Forbes" or "Company") announced today the sale of its...


Nycomed: Moving Ahead – Strong Results in Second Quarter 2008
Strong sales in key home markets Core products continue to develop very well Veltuzumab in-licensing significantly strengthens pipeline Oncology sale successfully closed The financial results reported in this press...


SymBio Pharmaceuticals and Eisai Sign License Agreement for bendamustine hydrochloride (SyB L-0501)
TOKYO, Aug. 18, 2008--SymBio Pharmaceuticals Limited. (Headquarters: Tokyo, President and CEO: Fuminori Yoshida, “SymBio”) and Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, “Eisai”) announced today...


Cytos Biotechnology and Pfizer Enter Into a Research, Option and License Agreement for Certain Novel Vaccines for a Defined Number of Human Diseases
Cytos Biotechnology is entitled to CHF 150 million in upfront and potential milestone payments as well as manufacturing technology transfer fees; in addition, it is eligible for research funding and royalties on net sales of products. SCHLIEREN...


Meda Acquires Product Portfolio from Roche
STOCKHOLM, Sweden--(BUSINESS WIRE)--Aug 15, 2008 Meda (STO:MEDAA) has reached an agreement with the Swiss pharma company Roche to acquire four of their well-established pharmaceutical products. The acquired products have strong brand names and the...


PAREXEL Closes the Acquisition of ClinPhone
Combined Capabilities Create the Industry's Largest eClinical Technology Offering BOSTON, August 14, 2008 /PRNewswire-FirstCall/ -- PAREXEL International Corporation , a leading global biopharmaceutical services organization, today announced the...


European Medicines Agency Update on Progressive Multifocal Leukoencephalopathy (PML) and Tysabri
LONDON, Aug. 13, 2008-At the end of July 2008, the European Medicines Agency (EMEA) received two reports of progressive multifocal leukoencephalopathy (PML) in patients with relapsing-remitting multiple sclerosis (MS) who have been treated with...


Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
BASINGSTOKE, England and CAMBRIDGE, Massachusetts, August 13, 2008 /PRNewswire-FirstCall/ -- Shire Limited , the global specialty biopharmaceutical company, today announced that since July 3, 2008 it has acquired 81% of the shares in Jerini AG...


Genentech Special Committee of Independent Directors Responds to Roche Proposal
SOUTH SAN FRANCISCO, Calif. -- August 13, 2008 -- The special committee of the Board of Directors of Genentech, Inc. (NYSE: DNA) announced that, after careful consideration, it has unanimously concluded that Roche's...


Talecris Enters into Definitive Merger Agreement with CSL
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aug 12, 2008 - Talecris Biotherapeutics, Inc. (www.talecris.com) today announced that it has signed a definitive merger agreement with CSL under which CSL has agreed to acquire Talecris for $3.1 billion...


Prime Therapeutics Releases Annual Drug Trend Insights Report
Annual spending on prescription drugs posts lowest increase ever recorded; rising acceptance of generic medications and flat usage rates offset effects of inflation ST. PAUL, Minn., August 13, 2008 /PRNewswire/ -- Prime Therapeutics, a thought...


Lipid Sciences Engages Rodman & Renshaw to Explore Strategic Options
PLEASANTON, CA, Aug 12, 2008 (MARKET WIRE via COMTEX News Network) -- Lipid Sciences, Inc. (NASDAQ: LIPD) announced today that the Board of Directors has authorized management to explore a broad range of strategic options to maximize shareholder...


Proton Pump Inhibitors Increase Risk of Bone Fractures
TORONTO, Aug. 11, 2008-Patients who use proton pump inhibitors for 7 or more years to treat reflux, peptic ulcers and other conditions are at greater risk of osteoporosis-related fractures, according to this large observational study,...


Schering-Plough Expands Its Presence in China, Enters Next Stage of Development
KENILWORTH, N.J., August 12, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that it has expanded its presence in China and established Shanghai Schering-Plough Pharmaceutical Co. Ltd., as a wholly owned operation based in...


Do-it-Yourself Botox, Not a Good Idea
NEW YORK, August 11, 2008 /PRNewswire-USNewswire/ -- The Physicians Coalition for Injectable Safety (http://www.injectablesafety.org) today cautions patients worldwide on the risks of buying cosmetic injectables from online sources. Websites...


Enrollment in Phase IIb Clinical Trial for I-vation TA (MK-0140) Suspended Pending Review of Study Design by Merck & Co., Inc.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Aug 8, 2008 - SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that Merck & Co., Inc. has informed the...


FDA MedWatch - Simvastatin Used With Amiodarone - Risk of Rhabdomyolysis When Simvastatin is Used With Amiodarone
ROCKVILLE, Md., Aug. 10, 2008-FDA notified healthcare professionals of the risk of muscle injury, rhabdomyolysis, which can lead to kidney failure or death, when simvastatin is used with amiodarone. This risk is dose-related and increases when a...


i3 Statprobe Selected to Assume Bulk of Lilly's U.S. Data Management Work
ANN ARBOR, Mich.--(BUSINESS WIRE)--Aug 8, 2008 - Pharmaceutical services company i3 announced today that global pharmaceutical firm Eli Lilly and Company (NYSE: LLY) is transferring the majority of its U.S. data management work to i3 Statprobe, a...


Gov. Patrick Should Veto the 'Pharmaceutical and Medical Device Manufacturer Conduct' Provision in S. 2863
WASHINGTON, August 08, 2008 /PRNewswire-USNewswire/ -- The Advanced Medical Technology Association (AdvaMed) urges Gov. Deval L. Patrick to veto the "Pharmaceutical and Medical Device Manufacturer Conduct" provision in S. 2863 because of the threat...


SEC Settles Civil Injunctive Action Against Former Executive of Massachusetts Public Company
WASHINGTON, Aug. 7, 2008-The Commission announced today that a final judgment by consent was entered by the United States District Court of the District of Massachusetts against Howard Richman, the former head of regulatory affairs of Biopure...


Bayer Acquires Preclinical Anti-Cancer Program From Nycomed
Bayer Schering Pharma strengthens its oncology R&D portfolio Bayer acquires Preclinical Anti-cancer Program from Nycomed Company assuming full development and commercialization rights BERLIN, August 7, 2008 - Bayer Schering Pharma AG, Germany,...


Novartis Begins Shipment to US of Fluvirin Influenza Virus Vaccine With Three New Strains for the 2008-2009 Influenza Season
Delivery of Fluvirin supports planning and scheduling of public health influenza vaccination efforts At least 20 million doses available by the end of September, when widespread vaccination campaigns usually begin Additional manufacturing capacity...


Spiriva, Micardis and Flomax - Boehringer Ingelheim`s Highly Successful Products Show Good Growth
- Excellent Progress in Research and Development. Strong Euro Curbs Growth. Expenditure in R&D+M Reduces Operating Income INGELHEIM/Germany, 7 August 2008 - The pharmaceutical company Boehringer Ingelheim continued to post strong growth in local...


New Podcast Series from Abbott for People Living with Crohn's Disease
'Crohn's Casts' offer insights from experts and people with Crohn's ABBOTT PARK, Illinois August 6, 2008 - ( NYSE: ABT) - As part of its ongoing commitment to the Crohn’s disease community, Abbott today launched a series of podcasts addressing...


GPC Biotech Reports that Celgene to Terminate Co-Development and License Agreement for Satraplatin
MARTINSRIED/MUNICH (Germany) and PRINCETON, N.J., August 6, 2008 - GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today reported that the Company has received notice from Celgene Corporation of its decision to terminate its...


King Pharmaceuticals Reports Second-Quarter 2008 Financial Results
BRISTOL, Tenn.--(BUSINESS WIRE)--Aug 7, 2008 - King Pharmaceuticals, Inc. (NYSE:KG) announced today that total revenues were $397 million during the second quarter ended June 30, 2008, compared to $543 million in the second quarter of 2007. This...


Publicis Groupe to Acquire Performics Search Marketing Business
Regulatory News: PARIS & MOUNTAIN VIEW, Calif., Aug. 6,2008--(BUSINESS WIRE)--Publicis Groupe (Paris:PUB) and Google (NASDAQ: GOOG) announced today that Publicis Groupe has agreed to acquire the Performics Search Marketing business (Performics)...


Covance and Lilly Enter Into a Strategic R&D Collaboration
- Covance to Acquire Lilly's Greenfield, Indiana Campus for $50 Million - Covance and Lilly Execute 10-Year, $1.6 Billion Services Contract Listen to the webcast. PRINCETON, N.J., Aug. 6 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), a leading...


UK Physicians Fear New Revalidation Procedures Will Reduce Morale, Decrease Time with Patients and Belittle GP Professionalism, According to New TNS Healthcare Research
LONDON, Aug. 6, 2008—Half of UK physicians believe that the new five-yearly revalidation process for doctors will belittle their professionalism, and 65% fear it will reduce morale, according to new TNS Healthcare research. In its study of...


Actavis Gets Go-Ahead for First Ever Oral Antibiotic Without Prescription in the UK – Clamelle to treat Chlamydia
HAFNARFJORDUR, Iceland, Aug. 6, 2008-Actavis welcomes the announcement that a pharmacy licence for azithromycin has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The successful application relates to the...


Lilly Sells its Greenfield, Indiana, Operations to Covance; Expands Existing Collaboration Between the Two Companies
Lilly to Lease New Elanco Global Headquarters in Hancock County, Indiana INDIANAPOLIS, August 06, 2008 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that Covance Inc. , one of the world's leading drug development services...


MedicinesRegulator Gives Go-Ahead For First Ever Oral Antibiotic to Be Made Available Without Prescription to Treat Chlamydia
LONDON, Aug. 6, 2008-The Medicines and Healthcare products Regulatory Agency (MHRA) has today given approval for a medicine to be made available from a pharmacist without a doctor's prescription to treat chlamydia. The azithromycin pill, which...


Valens Pharma Announces Next Steps
EDMONTON, Aug. 5 /CNW/ - Valens Pharma Ltd. (Valens, formerly known as "CardioMetabolics Inc."), today announced that the Company has suspended work on its DCA i.v program, a proprietary intravenous formulation of dichloroacetate pending further...


MDRNA, Inc. Announces Second Quarter 2008 Financial Results and Additional Corporate Restructuring
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 4, 2008--MDRNA, Inc. (Nasdaq: MRNA) today reported financial results for the three- and six-month periods ended June 30, 2008, and a further corporate restructuring. Revenue for the three months ended...


Home  |    Services   |   Resources   |   Site Map   |   Contact Us
Copy rights© reserved by ianadrol.com